|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.8398 - 0.8398|
|52-week range||0.8398 - 0.8398|
|Beta (5Y monthly)||1.79|
|PE ratio (TTM)||N/A|
|Earnings date||14 Nov 2022 - 18 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...